Article Text

Download PDFPDF
Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood
  1. Deshka Doycheva1,
  2. Manfred Zierhut1,
  3. Gunnar Blumenstock2,
  4. Bianka Sobolewska1,
  5. Bogomil Voykov1,
  6. Johanna Hohmann1,
  7. Martin S Spitzer1,
  8. Christoph Deuter1
  1. 1Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany
  2. 2Department of Clinical Epidemiology and Applied Biometry, University of Tuebingen, Tuebingen, Germany
  1. Correspondence to Dr Deshka Doycheva, Centre for Ophthalmology, University of Tuebingen, Schleichstrße, 12, Tuebingen 72076, Germany; deshka.doycheva{at}


Aim To assess the efficacy and tolerability of mycophenolate sodium (MPS) in the therapy of children with chronic non-infectious uveitis.

Methods Retrospective analysis of 23 children with chronic uveitis, treated with MPS, with a follow-up of at least 6 months. The main outcome measures were time to uveitis reactivation and corticosteroid-sparing effect under MPS treatment. The secondary outcome measures were best-corrected visual acuity (BCVA) and treatment-related side effects.

Results From 23 patients included in the study, 2 patients had anterior uveitis, 19 had intermediate uveitis and 2 had panuveitis. The probability of reactivation-free survival after MPS initiation was estimated as 65% at both 1 and 2 years. The probability of discontinuing systemic corticosteroids after 1 year of treatment was 39% and after 2 years 51%. The probability to taper corticosteroids to a daily dosage of ≤0.1 mg/kg after 1 and 2 years was 62% and 85%, respectively. BCVA improved or remained stable in 96% of eyes after 1 year of therapy. Treatment-related side effects were found in nine children (rate: 0.17/patient-year). No therapy discontinuation because of side effects was needed.

Conclusion Our data suggest that MPS is useful and well tolerated in children with chronic uveitis. MPS seems to be an effective drug for the treatment of chronic non-infectious uveitis of childhood and may be preferred as a first-line steroid-sparing agent in this form of uveitis.

  • Inflammation
  • Treatment Medical
  • Child health (paediatrics)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas